Phase I clinical trial of Zevalin (90Y-ibritumomab) in patients with B-cell non-Hodgkin's lymphoma (NHL) with relapsed disease following high-dose chemotherapy and autologous stem cell transplantation (ASCT).

被引：0
|
作者：
Vose, JM
Bierman, PJ
Lynch, JC
Bociek, GR
Multani, PS
Armitage, JO
机构：
[1] IDEC Corp, San Diego, CA USA
[2] Univ Nebraska, Med Ctr, Omaha, NE USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
92
引用
收藏
页码：30A / 30A
页数：1
相关论文
共 50 条
  • [21] High-Dose Chemotherapy (HDC) and Autologous Stem Cell Transplantation (ASCT) in patients with primary refractory aggressive Non-Hodgkin's lymphoma
    Rodriguez, J
    Caballero, MD
    Solano, C
    Lahuerta, JJ
    Arranz, R
    Sureda, A
    Zuazu, J
    Marin, J
    García-Laraña, J
    López-Guillermo, A
    SanMiguel, J
    Conde, E
    BONE MARROW TRANSPLANTATION, 2001, 27 : S260 - S261
  • [22] Assessment of Metabolic Response to Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
    Storto, Giovanni
    De Renzo, Amalia
    Pellegrino, Teresa
    Perna, Fabiana
    De Falco, Teresa
    Erra, Paola
    Nardelli, Anna
    Speranza, Antonio
    Klain, Michele
    Rotoli, Bruno
    Pace, Leonardo
    RADIOLOGY, 2010, 254 (01) : 245 - 252
  • [23] Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma
    Shimoni, Avichai
    Zwas, S. Tzila
    Oksman, Yakov
    Hardan, Izhar
    Shem-Tov, Noga
    Yerushalmi, Ronit
    Avigdor, Abraham
    Ben-Bassat, Isaac
    Nagler, Arnon
    EXPERIMENTAL HEMATOLOGY, 2007, 35 (04) : 534 - 540
  • [24] High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma
    Provencio, Mariano
    Fayad, Luis E.
    MEDICINA CLINICA, 2008, 130 (02): : 60 - 65
  • [25] Efficacy and safety of Yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL).
    Khouri, Issa F.
    Saliba, Rima M.
    Hosing, Chitra
    Valverde, Rosamar
    Erwin, William D.
    Fayad, Luis
    Maadani, Farzaneh
    Korbling, Martin J.
    Okoroji, Grace-Julia
    Stachowiak, Anne M.
    Samuels, Barry I.
    Anderlini, Paolo
    Couriel, Daniel R.
    de Lima, Marcos
    Giralt, Sergio
    Popat, Uday
    Kebriaei, Partow
    Ueno, Naoto T.
    Qazilbash, Muzaffar H.
    McLaughlin, Peter W.
    Hagemeister, Fredrick B.
    Younes, Anas
    Podoloff, Donald A.
    Champlin, Richard E.
    BLOOD, 2006, 108 (11) : 98A - 98A
  • [26] Yttrium-90 -: ibritumomab tiuxetan (Zevalin®) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin lymphoma
    Shimoni, A.
    Zwas, T.
    Oksman, Y.
    Hardan, I.
    Shem-Tov, N.
    Yerushalmi, R.
    Avigdor, A.
    Ben-Bassat, I.
    Nagler, A.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S145 - S145
  • [27] Late relapses following autologous hematopoietic stem cell (ASCT) transplantation for non-Hodgkin's lymphoma (NHL).
    Bierman, PJ
    Vose, JM
    Lynch, JC
    Bociek, RG
    Morris, ME
    Armitage, JO
    BLOOD, 1999, 94 (10) : 610A - 610A
  • [28] High-dose therapy and stem cell transplantation (BMT) for relapsed or refractory non-Hodgkin's lymphoma (NHL).
    Shahidi, H
    Gregory, SA
    GuptaBurt, S
    Adler, SS
    Venugopal, P
    Meyer, P
    Korenblit, AD
    Recine, D
    Manson, S
    Kaizer, H
    BLOOD, 1997, 90 (10) : 1023 - 1023
  • [29] Phase I trial combining 90Y Zevalin and high-dose BEAM chemotherapy with hematopoietic progenitor cell transplant in relapsed or refractory B-cell NHL.
    Winter, JN
    Inwards, D
    Erwin, W
    Wiseman, G
    Rademaker, A
    Patton, D
    Williams, S
    Tallman, M
    Mehta, J
    Singhal, S
    Micallef, I
    Spies, S
    Multani, P
    Zimmer, M
    White, C
    Gordon, LI
    BLOOD, 2001, 98 (11) : 677A - 678A
  • [30] Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma
    Winter, JN
    CLINICAL LYMPHOMA, 2004, 5 : S22 - S26
12345